BioCryst stock trades 1.47 percent below its prior close ahead of results

Published on 10/08/2026 at 19:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioCryst generated USD 218.25 million in the second quarter, up 33.60 percent year over year. BioCryst stock costs EUR 7.38 on October 8, 2026 after EUR 7.49.

Key points in brief

BioCryst stock was trading at EUR 7.38 at Lang & Schwarz on October 8, 2026, down 1.47 percent versus the prior close.
The second quarter of 2026 brought USD 218.25 million in revenue, up 33.60 percent year over year.
JPMorgan raised its BioCryst price target from USD 12.00 to USD 13.00 on September 30, 2026.
BioCryst is scheduled to report third-quarter 2026 results on November 2, 2026.

BCRX, US09058V1035, Illustration mit AI erstellt.

BioCryst Pharmaceuticals (ISIN US09058V1035) was trading at EUR 7.38 at Lang & Schwarz on October 8, 2026 at 7:08 p.m. CEST, down 1.47 percent versus the prior close of EUR 7.49. The next quarterly report is scheduled for November 2, 2026, according to MarketBeat.

Three milestones shape the stock

On May 6, 2026, BioCryst reported first-quarter revenue of USD 156.41 million, according to Simply Wall St. On August 5, 2026, second-quarter revenue reached USD 218.25 million, an increase of 33.60 percent from the prior year, while adjusted earnings per share came to USD 0.30 versus a USD 0.15 consensus estimate, MarketBeat reported.

On September 30, 2026, JPMorgan raised its price target from USD 12.00 to USD 13.00 while keeping a neutral rating, according to MarketBeat. The move puts the analyst target above the latest US market quote, but the Lang & Schwarz euro quote remains the reference price for investors in Germany.

What does the next report add?

BioCryst is due to report third-quarter 2026 results on November 2, 2026, before the market opens, with the conference call listed for 8:30 a.m. ET by MarketBeat. The comparison base is demanding: second-quarter revenue was USD 218.25 million, versus USD 183.28 million expected, and adjusted earnings per share exceeded the USD 0.15 estimate by USD 0.15.

Next dated reference point

The November 2 report is the next scheduled company event. The latest operating comparison remains the second quarter of 2026, when revenue rose 33.60 percent year over year and adjusted earnings per share reached USD 0.30.

Stock trades below its prior close

At Lang & Schwarz, BioCryst stock was trading at EUR 7.38 on October 8, 2026 at 7:08 p.m. CEST, down 1.47 percent versus the EUR 7.49 prior close from October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of BioCryst stock.